Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
BACKGROUND
The clinical management of community-acquired respiratory tract infections (RTIs) is complicated by the increasing worldwide prevalence of antibacterial resistance, in particular, beta-lactam and macrolide resistance, among the most common causative bacterial pathogens. This study aimed to determine the mechanisms and molecular- and sero-epidemiology of antibacterial resistance among the key paediatric respiratory pathogens in Japan.


METHODS
Isolates were collected at 18 centres in Japan during 2002 and 2003 from children with RTIs as part of the PROTEKT surveillance programme. A proportion of Haemophilus influenzae isolates was subjected to sequencing analysis of the ftsI gene; phylogenetic relatedness was assessed using multilocus sequence typing. Streptococcus pneumoniae isolates were screened for macrolide-resistance genotype by polymerase chain reaction and serotyped using the capsular swelling method. Susceptibility of isolates to selected antibacterials was performed using CLSI methodology.


CONCLUSIONS
Of the 557 H. influenzae isolates collected, 30 (5.4%) were beta-lactamase-positive [BL+], 115 (20.6%) were BL-nonproducing ampicillin-resistant (BLNAR; MIC >or= 4 mg/L) and 79 (14.2%) were BL-nonproducing ampicillin-intermediate (BLNAI; MIC 2 mg/L). Dabernat Group III penicillin binding protein 3 (PBP3) amino acid substitutions in the ftsI gene were closely correlated with BLNAR status but phylogenetic analysis indicated marked clonal diversity. PBP mutations were also found among BL+ and BL-nonproducing ampicillin-sensitive isolates. Of the antibacterials tested, azithromycin and telithromycin were the most active against H. influenzae (100% and 99.3% susceptibility, respectively). A large proportion (75.2%) of the 468 S. pneumoniae isolates exhibited macrolide resistance (erythromycin MIC >or= 1 mg/L); erm(B) was the most common macrolide resistance genotype (58.8%), followed by mef(A) (37.2%). The most common pneumococcal serotypes were 6B (19.7%), 19F (13.7%), 23F (13.5%) and 6A (12.8%). Telithromycin and amoxicillin-clavulanate were the most active antibacterials against S. pneumoniae (99.8% and 99.6% susceptibility, respectively).


CONCLUSIONS
Approximately one-third of H. influenzae isolates from paediatric patients in Japan are BLNAI/BLNAR, mainly as a result of clonally diverse PBP3 mutations. Together with the continued high prevalence of pneumococcal macrolide resistance, these results may have implications for the clinical management of paediatric RTIs in Japan.
Sunakawa
Keisuke
K
School of Medicine, Kitasato University, Kanagawa, Japan. sunakawa@med.kitasato-u.ac.jp
Farrell
David J
DJ
D000293:Adolescent; D019943:Amino Acid Substitution / Q000235:genetics; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000235:genetics; D002648:Child; D002675:Child, Preschool; D017714:Community-Acquired Infections / Q000453:epidemiology / Q000382:microbiology; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics*; D005260:Female; D005838:Genotype; D006192:Haemophilus Infections / Q000453:epidemiology / Q000382:microbiology; D006193:Haemophilus influenzae / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan / Q000453:epidemiology; D018942:Macrolides / Q000494:pharmacology*; D008297:Male; D008826:Microbial Sensitivity Tests; D046915:Penicillin-Binding Proteins / Q000235:genetics; D010802:Phylogeny; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology; D016133:Polymerase Chain Reaction; D012141:Respiratory Tract Infections / Q000453:epidemiology / Q000382:microbiology*; D017422:Sequence Analysis, DNA; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D001618:beta-Lactamases / Q000096:biosynthesis; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D018942:Macrolides; D046915:Penicillin-Binding Proteins; D047090:beta-Lactams; D001618:beta-Lactamases
J Antimicrob Chemother. 2000 Feb;45(2):191-203
10660501
Clin Infect Dis. 1998 Apr;26(4):811-38
9564457
Semin Respir Infect. 2000 Sep;15(3):184-94
11052419
J Antimicrob Chemother. 2001 Oct;48(4):541-4
11581234
Antimicrob Agents Chemother. 2002 Jul;46(7):2208-18
12069976
J Infect. 2002 Feb;44 Suppl A:3-10
12150493
Antimicrob Agents Chemother. 2003 Feb;47(2):489-93
12543648
J Antimicrob Chemother. 2002 Dec;50 Suppl S2:59-73
12556435
J Infect Chemother. 2003 Mar;9(1):46-52
12673407
J Clin Microbiol. 2003 Apr;41(4):1623-36
12682154
Microb Drug Resist. 2003 Spring;9(1):39-46
12705682
Clin Microbiol Infect. 2003 Jul;9(7):653-61
12925106
Pediatr Infect Dis J. 2003 Aug;22(8 Suppl):S109-19
14566997
J Antimicrob Chemother. 2003 Dec;52(6):1018-21
14585854
J Infect. 2004 Jan;48(1):39-55
14667791
Am J Med Sci. 2003 Dec;326(6):360-8
14671500
J Med Microbiol. 2004 Nov;53(Pt 11):1109-17
15496389
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7
9021182
Microb Drug Resist. 1995 Summer;1(2):131-5
9158746
J Antimicrob Chemother. 2000 Jun;45(6):871-5
10837442